Pesquisar
Barinthus Biotherapeutics PLC
BRNSAdicionar à lista de desejos
0.640USD
-0.020-3.02%
Fechamento 07/01, 16:00（ET）Cotações atrasadas em 15 min
26.18MValor de mercado
PerdaP/L TTM
Mais detalhes de Barinthus Biotherapeutics PLC Empresa
Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company focused on developing immunotherapeutic candidates for treating autoimmune and inflammatory diseases. The Company’s pipeline, built around platform technologies; viral vector-based, consists of ChAdOx and MVA, and synthetic, consisting of SNAP-Tolerance Immunotherapy (SNAP-TI). These platforms help to develop antigen-specific immunotherapeutic candidates designed to optimize the disease fighting capabilities of T cells. It is focused on developing two product candidates that harness its viral vector and synthetic platform technologies. These include VTP-300, a Phase II immunotherapeutic candidate designed as a potential component of a functional cure for chronic hepatitis B virus infection utilizing ChAdOx/MVA, and VTP-1000, its autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease. The Company's pipeline also includes VTP-850, VTP-500 and VTP-400.
Informações de Barinthus Biotherapeutics PLC
Código da empresaBRNS
Nome da EmpresaBarinthus Biotherapeutics PLC
Data de listagemApr 30, 2021
CEOEnright (William J)
Número de funcionários105
Tipo de títulosDepository Receipt
Fim do ano fiscalApr 30
EndereçoUnit 6-10, Zeus Building, Rutherford Avenue
CidadeDIDCOT
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited Kingdom
Código postalOX11 0DF
Telefone441865818808
Sitehttps://www.barinthusbio.com/
Código da empresaBRNS
Data de listagemApr 30, 2021
CEOEnright (William J)
Executivos da empresa Barinthus Biotherapeutics PLC
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Geoffrey Lynn
Dr. Geoffrey Lynn
Chief Scientific Officer
Chief Scientific Officer
640.64K
--
Mr. Robin Wright
Mr. Robin Wright
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
48.26K
--
Dr. Pierre A. Morgon, Pharm.D.
Dr. Pierre A. Morgon, Pharm.D.
Non-Executive Independent Director
Non-Executive Independent Director
10.51K
--
Dr. Anne M. Phillips, M.D.
Dr. Anne M. Phillips, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
3.00K
--
Mr. William J. (Bill) Enright
Mr. William J. (Bill) Enright
Chief Executive Officer, Principal Financial Officer, Director
Chief Executive Officer, Principal Financial Officer, Director
--
--
Dr. Alex Hammacher
Dr. Alex Hammacher
Non-Executive Director
Non-Executive Director
--
--
Ms. Karen T. Dawes
Ms. Karen T. Dawes
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Joseph C. Scheeren
Dr. Joseph C. Scheeren
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Leon Hooftman, M.D.
Dr. Leon Hooftman, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Geoffrey Lynn
Dr. Geoffrey Lynn
Chief Scientific Officer
Chief Scientific Officer
640.64K
--
Mr. Robin Wright
Mr. Robin Wright
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
48.26K
--
Dr. Pierre A. Morgon, Pharm.D.
Dr. Pierre A. Morgon, Pharm.D.
Non-Executive Independent Director
Non-Executive Independent Director
10.51K
--
Dr. Anne M. Phillips, M.D.
Dr. Anne M. Phillips, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
3.00K
--
Mr. William J. (Bill) Enright
Mr. William J. (Bill) Enright
Chief Executive Officer, Principal Financial Officer, Director
Chief Executive Officer, Principal Financial Officer, Director
--
--
Dr. Alex Hammacher
Dr. Alex Hammacher
Non-Executive Director
Non-Executive Director
--
--
Perguntas frequentes
Quem são os cinco principais acionistas de Barinthus Biotherapeutics PLC?
Os cinco principais acionistas de Barinthus Biotherapeutics PLC são: Dr. Geoffrey Lynn
Quantas instituições possuem ações da Barinthus Biotherapeutics PLC (BRNS)?
Em 2026Q1, 32 instituições possuíam ações da Barinthus Biotherapeutics PLC, com valor de mercado aproximado de 16.70M, representando 40.87% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -1943125.00.